RaySight Medical Secures Hundreds of Millions in Series C Funding to Build the World's First Precision AI-Powered Integrated Cardio-Cerebrovascular Diagnosis and Treatment Platform

Recently, Shenzhen Raysightmed Co., Ltd. (RaysightMed) announced the completion of its Series C financing round, raising hundreds of millions of RMB. According to reports, the round was led by SDIC Capital, with existing shareholders continuing to reinvest. China Renaissance served as the exclusive financial advisor.

RaysightMed is an innovative medical technology company that initiated its product R&D with CT-FFR (non-invasive fractional flow reserve) and has since expanded into artificial intelligence and precision diagnosis and treatment for cardiovascular and cerebrovascular diseases. Over the three-plus years since its establishment, it has successively completed five rounds of financing. In April this year, RaysightMed received approval for China's first CT-FFR product based on scientific computing (computational fluid dynamics): the Raysight Score. Additionally, the company launched the world's first innovative diagnostic and therapeutic platform in the cardiovascular field that integrates "morphological" and "functional" assessments.

It is understood that this round of financing will be utilized to accelerate the market commercialization of the product portfolio, drive the large-scale deployment of service scenarios, and expand the technical team, while attracting cutting-edge talent to participate in innovative R&D, thereby comprehensively and deeply advancing the implementation of RaysightMed's "professional, precise, distinctive, and innovative" intelligent diagnosis and treatment platform.

In early 2021, the Ministry of Finance and the Ministry of Industry and Information Technology (hereinafter collectively referred to as the two departments) jointly issued the *Notice on Supporting the High-Quality Development of "Specialized, Refined, Distinctive, and Innovative" Small and Medium-Sized Enterprises*, officially launching the central fiscal support policy for the high-quality development of "specialized, refined, distinctive, and innovative" SMEs.

To date, RaysightMed's product services have comprehensively covered diagnostic and therapeutic scenarios across cardiovascular, cerebrovascular, and peripheral vascular fields, achieving refined application coverage spanning from preoperative assessment, risk analysis, surgical planning, medical device simulation and selection, intraoperative navigation, outcome evaluation, to postoperative follow-up. It is reported that, in addition to Raysight FFR, several other products—including the intelligent coronary post-processing platform, the cerebrovascular perfusion assessment platform, and the intelligent peripheral vascular imaging processing platform—are successively entering the final stages of clinical trials and imminent market approval. It is expected that by 2022, the first specialized, precise, non-invasive, and intelligent cardio-cerebrovascular integrated full-course diagnosis and treatment management platform will be fully implemented, with the entire product portfolio projected to reach a market value of hundreds of billions of RMB.

Ma Jun, CTO of RaysightMed, emphasized: "The key to ensuring that a product can withstand iterative updates and establish a differentiated advantage lies in how innovative technologies are applied and how the technological novelty of the product is maintained." It is reported that one of the technological barriers of the Raysight Score—its full 3D CFD (Computational Fluid Dynamics) simulation—is fundamentally physics-based and can accommodate more complex lesion conditions, thereby avoiding the uninterpretable and non-scalable drawbacks of deep learning "black boxes." In terms of image processing, RaysightMed's R&D employs a proprietary secondary segmentation technology, which significantly enhances the segmentation accuracy of coronary artery models. Through multiple comparative studies, its segmentation precision has been shown to closely approach that of IVUS (Intravascular Ultrasound) and coronary angiography images. Furthermore, across its entire product portfolio, RaysightMed has comprehensively optimized the calculation algorithms for patients' physiological parameters by extensively collecting historical real-world clinical data, ensuring that current computational results better align with the physiological characteristics of the Chinese population.

According to reports, RaysightMed's specialized R&D team accounts for over half of its total workforce. All members of the core technical team have previously worked for many years at leading global medical device companies such as GE, Siemens, and Intuitive Surgical (maker of the da Vinci surgical robot). The remaining members are alumni of prestigious institutions including Johns Hopkins University, Tulane University, Stanford University, the University of Michigan, Tsinghua University, Beihang University, and Wuhan University, and have accumulated extensive expertise in artificial intelligence and computational fluid dynamics.

With the continuous expansion of its product portfolio and the commercial launch of the Raysight FFR, RaysightMed is significantly scaling up its R&D and sales teams. According to industry reports, the company's business teams consist of veterans from top multinational and leading state-owned medical device enterprises in the cardiovascular and cerebrovascular sectors, bringing deep industry expertise and a robust sales channel network. To date, the Raysight FFR has been deployed in over 500 Grade A tertiary hospitals in China, with clinical applications exceeding 50,000 cases. Furthermore, the product is currently pursuing CE marking in Europe and FDA approval in the United States, and is poised for an imminent global launch.

SDIC China Merchants Life Sciences TeamStated: China is home to nearly 300 million cardiovascular disease patients, and the annual volume of coronary CTA procedures has already exceeded 10 million. CT-FFR has been validated by numerous domestic and international clinical trials as a safe, effective, and precise method for coronary assessment. Furthermore, since CT-FFR is derived from non-invasive CTA imaging, it is highly suitable for large-scale screening of cardiovascular and cerebrovascular diseases, effectively serving as a gatekeeper prior to patients undergoing coronary angiography. Therefore, CT-FFR is poised to cultivate a market worth tens of billions of RMB in the coming years. As a domestic pioneer, RaysightMed possesses exceptional product R&D capabilities within the industry, and we maintain a highly optimistic long-term outlook for the company's future development. SDIC Capital is honored to partner with industry leader RaysightMed, working together to contribute to the prevention and treatment of cardiovascular diseases in China.

Yijing Xie, Managing Director and Head of Healthcare & Life Sciences Group at China RenaissanceStated: AI technology and smart healthcare will be the defining themes of the medical technology sector over the next decade. As a trend-setting product that has already achieved large-scale clinical application and commercialization in cardiovascular and cerebrovascular care, CT-FFR has consistently attracted significant market attention. China Renaissance is honored to continue serving RaysightMed, and we believe the company will become China’s leading enterprise transitioning from intelligent diagnosis and treatment to a comprehensive clinical platform for cardiovascular and cerebrovascular diseases. China Renaissance will continue to empower the rapid development of RaysightMed.

RaysightMed CEO Zheng LingxiaoIt was stated that this financing will support RaysightMed in continuing to take “specialized, refined, distinctive, and innovative” development as its driving force and strategic direction, continuously strengthening its hard-tech capabilities. In fact, there is no such thing as ‘overtaking on a curve’ in the development of innovative medical devices. Behind every product application lies a highly meticulous and rigorous process: R&D, validation, clinical trials, post-approval real-world studies, large-scale clinical applications, and more. We are grateful for the encouragement and trust from SDIC Capital and our existing shareholders. Moving forward, RaysightMed will continue to advance steadily and reliably, delivering a globally leading product portfolio to patients and healthcare professionals.